Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 3/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.43 |
| ▸ | LTA4H | P09960 | 5/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7110081 | 0.83 | EBP (0.51) | EBPSIGMAR1ESR1ESR2LTA4H | |
| SCHEMBL7112790 | 0.80 | ESR1 (0.58) | EBPSIGMAR1ESR1ESR2LTA4H | |
| SCHEMBL7110644 | 0.79 | EBP (0.49) | EBPSIGMAR1ESR1ESR2LTA4H | |
| SCHEMBL7106075 | 0.78 | EBP (0.51) | EBPSIGMAR1ESR1ESR2LTA4H | |
| SCHEMBL7113233 | 0.76 | EBP (0.46) | EBPSIGMAR1ESR1ESR2LTA4H | |
| SCHEMBL7111793 | 0.76 | EBP (0.57) | EBPSIGMAR1ESR1ESR2LTA4H | |
| SCHEMBL7109915 | 0.75 | EBP (0.58) | EBPSIGMAR1ESR1ESR2LTA4H | |
| SCHEMBL7111176 | 0.75 | EBP (0.47) | EBPSIGMAR1ESR1ESR2LTA4H | |
| SCHEMBL7110875 | 0.74 | EBP (0.58) | EBPSIGMAR1ESR1ESR2LTA4H | |
| SCHEMBL7106078 | 0.74 | EBP (0.49) | EBPSIGMAR1ESR1ESR2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | NDC1, SQLE, NQO1 | EBP 1842/4885SIGMAR1 1661/4885ESR1 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.